Clinical Implications of Early vs Late Development of Donor-Specific Antibodies After Lung Transplant
Purpose: Lung transplant recipients (LTRs) can develop donor specific antibodies (DSAs), which are associated with antibody-mediated rejection (AMR). LTRs at our center undergo regular DSA surveillance in the first year post-LT, and LTRs that develop DSAs are treated, even in the absence of allograft dysfunction. These treatments are burdensome to patients and carry a significant risk of adverse effects. Thus, we sought to compare the clinical outcomes of LTRs without DSAs to those that develop DSAs early post-LT (
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: , N. Kohler, G. Bitar, B. Franz, C. Mitchell, C. Pham, K. Grief, R. Walia, S. Tokman Source Type: research
More News: Bone Graft | Cardiology | Heart | Heart Transplant | Lung Transplant | Transplant Surgery | Transplants